GSK links with CEPI to develop a vaccine for the 2019-nCoV virus

3 February 2020

UK pharma major GlaxoSmithKline (LSE: GSK) today announced a new collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) aimed at helping the global effort to develop a vaccine for the 2019-nCoV virus.

In this new move, GSK will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against the novel coronavirus that originated in China’s Wuhan City and has spread rapidly across the country as well as abroad. The latest figures show that 261 people have died and more than 17,000 have been identified as infected with the virus.

GSK is a leader in the development of innovative vaccines using different adjuvant systems. The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and made available to more people.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK